Molecular aspects of monoamine oxidase B

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 69, Issue , 2016, Pages 81-89

  Ramsay, Rona R ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Drug design; Kinetics; Monoamine oxidase B; Neurotransmitter levels; Platelet

Indexed keywords

AMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; HYDROGEN PEROXIDE; MESSENGER RNA; MONOAMINE; MONOAMINE OXIDASE B INHIBITOR; OXYGEN; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR;

ADDICTION; AGING; ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING KINETICS; BRAIN LEVEL; CHEMICAL REACTION; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC VARIATION; HUMAN; IMIDAZOLINE I2 SITE; IRON CHELATION; MICRODIALYSIS; MONOAMINE METABOLISM; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; THROMBOCYTE; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

ANIMALS; BRAIN; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS;

EID: 84975709281     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.02.005     Document Type: Article

References (131)

1. Abad E., Zenn R.K., Kaestner J. Reaction mechanism of monoamine oxidase from QM/MM calculations. J. Phys. Chem. B 2013, 117:14238-14246.
2. Adolfsson R., Gottfries C.G., Oreland L., Wiberg A., Winblad B. Increased activity of brain and platelet monoamine-oxidase in dementia of Alzheimer type. Life Sci. 1980, 27:1029-1034.
3. Aklillu E., Karlsson S., Zachrisson O.O., Ozdemir V., Agren H. Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. Pharmacogenet. Genomics 2009, 19:267-275.
4. Aluf Y., Vaya J., Khatib S., Loboda Y., Finberg J.P.M. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway. Neuropharmacology 2013, 65:48-57.
5. Andreou D., Soderman E., Axelsson T., Sedvall G.C., Terenius L., Agartz I., et al. Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis. Behav. Brain Funct. 2014, 10.
6. Balciuniene J., Emilsson L., Oreland L., Pettersson U., Jazin E.E. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum. Genet. 2002, 110:1-7.
7. Basile L., Pappalardo M., Guccione S., Milardi D., Ramsay R.R. Computational comparison of imidazoline association with the 12 binding site in human monoamine oxidases. J. Chem. Inf. Model. 2014, 54:1200-1207.
8. Bautista-Aguilera O.M., Samadi A., Chioua M., Nikolic K., Filipic S., Agbaba D., et al. N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4yl)propoxy)-1h-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase inhibitor. J. Med. Chem. 2014, 57:10455-10463.
9. Bazzu G., Rocchitta G., Migheli R., Md Alvau, Zinellu M., Puggioni G., et al. Effects of the neurotoxin MPTP and pargyline protection on extracellular energy metabolites and dopamine levels in the striatum of freely moving rats. Brain Res. 2013, 1538:159-171.
10. Beaulieu J.-M., Espinoza S., Gainetdinov R.R. Dopamine receptors - IUPHAR review 13. Br. J. Pharmacol. 2015, 172:1-23.
11. Bianchi P., Kunduzova O., Masini E., Cambon C., Bani D., Raimondi L., et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 2005, 112:3297-3305.
12. Binda C., De Colibus L., Edmondson D.E., Mattevi A. 2BYB: Human Monoamine Oxidase B in Complex With Deprenyl 2005, Protein Data Bank.
13. Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D.E., et al. Binding of rasagiline-related inhibitors to human monoamine oxidases. A kinetic and crystallographic analysis. J. Med. Chem. 2005, 48:8148-8154.
14. Binda C., Li M., Hubalek F., Restelli N., Edmondson De, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9750-9755.
15. Bolea I., Colivicchi M.A., Ballini C., Marco-Contelles J., Tipton K.F., Unzeta M., et al. Neuroprotective effects of the MAO B inhibitor, PF9601N, in an in vivo model of excitotoxicity. CNS Neurosci. Ther. 2014, 20:641-650.
16. Bonivento D., Milczek E.M., Mcdonald G.R., Binda C., Holt A., Edmondson De, et al. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J. Biol. Chem. 2010, 285:36849-36856.
17. Bortolato M., Shih Jc Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int. Rev. Neurobiol. 2011, 100:13-42.
18. Bortolato M., Godar S.C., Davarian S., Chen K., Shih J.C. Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice. Neuropsychopharmacology 2009, 34:2746-2757.
19. Brunner H.G., Nelen M., Breakefield X.O., Ropers Hh., Vanoost B.A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase-A. Science 1993, 262:578-580.
20. Butcher S.P., Fairbrother I.S., Kelly J.S., Arbuthnott G.W. Effects of selective monoamine-oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 1990, 55:981-988.
21. Carradori S., Silvestri R. New frontiers in selective human MAO B inhibitors. J. Med. Chem. 2015, 58:6717-6732.
22. Chen K., Holschneider D.P., WH Wu, Rebrin I., Shih J.C. A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. J. Biol. Chem. 2004, 279:39645-39652.
23. Coccini T., Castoldi A.F., Gandini C., Randine G., Vittadini G., Baiardi P., et al. Platelet monoamine oxidase B activity as a state marker for alcoholism: trend over time during withdrawal and influence of smoking and gender. Alcohol Alcohol. 2002, 37:566-572.
24. Dammann G., Teschler S., Haag T., Altmueller F., Tuczek F., Dammann Rh. Increased DNA methylation of neuropsychiatric genes occurs in borderline personality disorder. Epigenetics 2011, 6:1454-1462.
25. De Benedetto G.E., Fico D., Pennetta A., Malitesta C., Nicolardi G., Lofrumento D.D., et al. A rapid and simple method for the determination of 3,4-dihydroxyphenylacetic acid, norepinephrine, dopamine, and serotonin in mouse brain homogenate by HPLC with fluorimetric detection. J. Pharm. Biomed. Anal. 2014, 98:266-270.
26. Deftereos Sn, Dodou E., Andronis C., Persidis A. From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. Expert. Rev. Clin. Pharmacol. 2012, 5:413-425.
27. Dhondt Jl, Forzy G. Usual values for 5-hydroxy-indol acetic acid and homovanillic acid in cerebrospinal fluid. Ann. Biol. Clin. 2003, 61:69-75.
28. Dingemanse J., Kneer J., Wallnofer A., Kettler R., Zurcher G., Koulu M., et al. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin. Neuropharmacol. 1996, 19:399-414.
29. Edmondson De, Binda C., Mattevi A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys. 2007, 464:269-276.
30. Edmondson De, Binda C., Wang J., Upadhyay Ak, Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 2009, 48:4220-4230.
31. Esteban G., Allan J., Samadi A., Mattevi A., Unzeta M., Marco-Contelles J., et al. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. BBA Proteins Proteom. 2014, 1844:1104-1110.
32. Farina R., Pisani L., Catto M., Nicolotti O., Gadaleta D., Denora N., et al. Structure-based design and optimization of multitarget-directed 2h-chromen-2-one derivatives as potent inhibitors of monoamine oxidase B and cholinesterases. J. Med. Chem. 2015, 58:5561-5578.
33. Fisar Z., Hroudova J., Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuroendocrinol. Lett. 2010, 31:645-656.
34. Flik G., Folgering Jha, Cremers Tihf, Westerink Bhc, Dremencov E. Interaction between brain histamine and serotonin, norepinephrine, and dopamine systems: in vivo microdialysis and electrophysiology study. J. Mol. Neurosci. 2015, 56:320-328.
35. Fowler Cj, Oreland L. The nature of the substrate-selective interaction between rat-liver mitochondrial monoamine-oxidase and oxygen. Biochem. Pharmacol. 1980, 29:2225-2233.
36. Fowler Js, Logan J., Shumay E., Alia-Klein N., Wang G.-J., Volkow Nd Monoamine oxidase: radiotracer chemistry and human studies. J. Label. Compd. Radiopharm. 2015, 58:51-64.
37. Fowler Js, Logan J., Volkow Nd, Wang Gj Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol. Imaging Biol. 2005, 7:377-387.
38. Fowler Js, Volkow Nd, Wang Gj, Pappas N., Logan J., Macgregor R., et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996, 379:733-736.
39. Gal S., Zheng H., Fridkin M., Youdim Mbh Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 2005, 95:79-88.
40. Garpenstrand H., Ekblom J., Forslund K., Rylander G., Oreland L. Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. J. Neural Transm. 2000, 107:523-530.
41. Geldenhuys W.J., Van Der Schyf C.J. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr. Med. Chem. 2013, 20:1662-1672.
42. Gillman P.K. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J. Clin. Psychopharmacol. 2011, 31:66-74.
43. Gu H., Varner E.L., Groskreutz S.R., Michael A.C., Weber S.G. In vivo monitoring of dopamine by microdialysis with 1 min temporal resolution using online capillary liquid chromatography with electrochemical detection. Anal. Chem. 2015, 87:6088-6094.
44. Hara M.R., Thomas B., Cascio M.B., Bae B.I., Hester L.D., Dawson Vl, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3887-3889.
45. Hauptmann N., Grimsby J., Shih J.C., Cadenas E. The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch. Biochem. Biophys. 1996, 335:295-304.
46. Holschneider D.P., Chen K., Seif I., Shih J.C. Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res. Bull. 2001, 56:453-462.
47. Hubalek F., Binda C., Li M., Herzig Y., Sterling J., Youdim M.B.H., et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J. Med. Chem. 2004, 47:1760-1766.
48. Hyland K. Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid. Clin. Chem. 2008, 54:633-641.
49. Ihle E.C., Van Der Hart M., Jongsma M., Tecott Lh., Doupe A.J. Dopamine physiology in the basal ganglia of male zebra finches during social stimulation. Eur. J. Neurosci. 2015, 41:1506-1514.
50. Jones T.Z.E., Giurato L., Guccione S., Ramsay R.R. Interactions of imidazoline ligands with the active site of purified monoamine oxidase A. FEBS J. 2007, 274:1567-1575.
51. Kaludercic N., Mialet-Perez J., Paolocci N., Parini A., Di Lisa F. Monoamine oxidases as sources of oxidants in the heart. J. Mol. Cell. Cardiol. 2014, 73:34-42.
52. Kay Cwm, El Mkami H., Molla G., Pollegioni L., Ramsay R.R. Characterization of the covalently bound anionic flavin radical in monoamine oxidase A by electron paramagnetic resonance. J. Am. Chem. Soc. 2007, 129:16091-16097.
53. Kealey S., Turner E.M., Husbands S.M., Salinas C.A., Jakobsen S., Tyacke R.J., et al. Imaging imidazoline-I-2 binding sites in porcine brain using C-11-BU99008. J. Nucl. Med. 2013, 54:139-144.
54. Keller B., Garcia-Sevilla J.A. Immunodetection and subcellular distribution of imidazoline receptor proteins with three antibodies in mouse and human brains: effects of treatments with I-1- and I-2-imidazoline drugs. J. Psychopharmacol. 2015, 29:996-1012.
55. Kennedy B.P., Ziegler M.G., Alford M., Hansen L.A., Thal L.J., Masliah E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. J. Neural Transm. 2003, 110:789-801.
56. Kupershmidt L., Amit T., Bar-Am O., Weinreb O., Youdim M.B.H. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice. Mol. Neurobiol. 2012, 46:217-220.
57. Lamensdorf I., Youdim M.B.H., Finberg J.P.M. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem. 1996, 67:1532-1539.
58. Lanza M., Ferrari F., Menghetti I., Tremolada D., Caselli G. Modulation of imidazoline I-2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats. Br. J. Pharmacol. 2014, 171:3693-3701.
59. Launay J.-M., Del Pino M., Chironi G., Callebert J., Peoc'h K., Megnien J.-L., et al. Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PLoS One 2009, 4. 10.1371/Journal.Pone.0007959.
60. Lenders J.W.M., Eisenhofer G., Abeling N., Berger W., Murphy D.L., Konings Ch., et al. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J. Clin. Investig. 1996, 97:1010-1019.
61. Liu Y., Wang Z., Zhang B. The relationship between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease risk: a meta-analysis. Ann. Saudi Med. 2014, 34:12-17.
62. Lum C.T., Stahl S.M. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr. 2012, 17:107-120.
63. Macmillar S., Edmondson D.E., Matsson O. Nitrogen kinetic isotope effects for the monoamine oxidase B-catalyzed oxidation of benzylamine and (1,1-H-2(2))benzylamine: nitrogen rehybridization and CH bond cleavage are not concerted. J. Am. Chem. Soc. 2011, 133:12319-12321.
64. Malmlof T., Feltmann K., Konradsson-Geuken A., Schneider F., Alken R.-G., Svensson T.H., et al. Deuterium-substituted l-dopa displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by l-dopa and an MAO B inhibitor. J. Neural Transm. 2015, 122:259-272.
65. Manuck S.B., Flory J.D., Re Ferrell, Mann J.J., Muldoon M.F. A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatry Res. 2000, 95:9-23.
66. McCormack P.L. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. CNS Drugs 2014, 28:1083-1097.
67. McCorvy J.D., Roth B.L. Structure and function of serotonin G protein-coupled receptors. Pharmacol. Ther. 2015, 150:129-142.
68. McDonald G.R., Olivieri A., Ramsay R.R., Holt A. On the formation and nature of the imidazoline I(2) binding site on human monoamine oxidase-B. Pharmacol. Res. 2010, 62:475-488.
69. Mercimek-Mahmutoglu S., Sidky S., Patel J., Kyriakopoulou L., Hyland K. Retrospective review of cerebrospinal fluid catecholamine and serotonin metabolites for indications and diagnosis of neurotransmitter disorders. Mol. Genet. Metab. 2014, 111:279-280.
70. Meyer J.H., Ginovart N., Boovariwala A., Sagrati S., Hussey D., Garcia A., et al. Elevated monoamine oxidase A levels in the brain - an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 2006, 63:1209-1216.
71. Mitchell D.J., Nikolic D., Van Breemen R.B., Silverman R.B. Inactivation of monoamine oxidase B by 1-phenylcyclopropylamine: mass spectral evidence for the flavin adduct. Bioorg. Med. Chem. Lett. 2001, 11:1757-1760.
72. Moraes F.P., De Azevedo W.F. Targeting imidazoline site on monoamine oxidase B through molecular docking simulations. J. Mol. Model. 2012, 18:3877-3886.
73. Moron J.A., Perez V., Pasto M., Lizcano J.M., Unzeta M. Fa-70, a novel selective and irreversible monoamine oxidase-A inhibitor: effect on monoamine metabolism in mouse cerebral cortex. J. Pharmacol. Exp. Ther. 2000, 292:788-794.
74. Murphy B.P., Chung Y.-C., Park T.-W., Mcgorry P.D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr. Res. 2006, 88:5-25.
75. Murphy D.L., Sims K.B., Karoum F., Delachapelle A., Norio R., Sankila E.M., et al. Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine-oxidase. J. Neurochem. 1990, 54:242-247.
76. Murray At, Dowley M.J.H., Pradaux-Caggiano F., Baldansuren A., Fielding A.J., Tuna F., et al. Catalytic amine oxidation under ambient aerobic conditions: mimicry of monoamine oxidase B. Angew. Chem. Int. Ed. 2015, 54:8997-9000.
77. Naoi M., Maruyama W. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr. Pharm. Des. 2010, 16:2799-2817.
78. Naoi M., Maruyama W., Inaba-Hasegawa K. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert. Rev. Neurother. 2013, 13:671-684.
79. Newton-Vinson P., Hubalek F., Edmondson D.E. High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr. Purif. 2000, 20:334-345.
80. Nicotra A., Pierucci F., Parvez H., Senatori O. Monoamine oxidase expression during development and aging. Neurotoxicology 2004, 25:155-165.
81. Nikolic K., Agbaba D. Pharmacophore development and SAR studies of imidazoline receptor ligands. Mini-Rev. Med. Chem. 2012, 12:1542-1555.
82. Nikolic K., Mavridis L., Bautista-Aguilera O.M., Marco-Contelles J., Stark H., Carreiras M.D.C., et al. Predicting targets of compounds against neurological diseases using cheminformatic methodology. J. Comput. Aided Mol. Des. 2015, 29:183-198.
83. Ooi J., Hayden M.R., Pouladi M.A. Inhibition of excessive monoamine oxidase A/B activity protects against stress-induced neuronal death in Huntington disease. Mol. Neurobiol. 2015, 52:1850-1861.
84. Oreland L. Platelet monoamine oxidase, personality and alcoholism: the rise, fall and resurrection. Neurotoxicology 2004, 25:79-89.
85. Oreland L., Hallman J. The correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanisms. Prog. Brain Res. 1995, 106:77-84.
86. Oreland L., Nilsson K., Damberg M., Hallman J. Monoamine oxidases - activities, genotypes and the shaping of behaviour. J. Neural Transm. 2007, 114:817-822.
87. Pearce L.B., Roth J.A. Human-brain monoamine-oxidase type-B - mechanism of deamination as probed by steady-state methods. Biochemistry 1985, 24:1821-1826.
88. Philibert R.A., Beach S.R.H., Gunter T.D., Brody G.H., Madan A., Gerrard M. The Effect of Smoking on MAOA Promoter Methylation in DNA Prepared From Lymphoblasts and Whole Blood. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153b:619-628.
89. Qiu Y., Thorn Da, Zhang Y., He X., Li J.-X. Behavioral effects of the imidazoline I-2 receptor ligand BU99006 in rats. Behav. Pharmacol. 2014, 25:130-136.
90. Qiu Y., Zhang Y., Li J.-X. Discriminative stimulus effects of the imidazoline I-2 receptor ligands BU224 and phenyzoline in rats. Eur. J. Pharmacol. 2015, 749:133-141.
91. Ramsay R.R. Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery. Curr. Top. Med. Chem. 2012, 12:2189-2209.
92. Ramsay R.R., Koerber S.C., Singer T.P. Stopped-flow studies on the mechanism of oxidation of N-methyl-4-phenyltetrahydropyridine by bovine liver monoamine oxidase-B. Biochemistry 1987, 26:3045-3050.
93. Ramsay R.R., Olivieri A., Holt A. An improved approach to steady-state analysis of monoamine oxidases. J. Neural Transm. 2011, 118:1003-1019.
94. Repic M., Vianello R., Purg M., Duarte F., Bauer P., Kamerlin S.C.L., et al. Empirical valence bond simulations of the hydride transfer step in the monoamine oxidase B catalyzed metabolism of dopamine. Proteins: Struct., Funct., Bioinf. 2014, 82:3347-3355.
95. Sader-Mazbar O., Loboda Y., Rabey M.J., Finberg J.P.M. Increased l-dopa-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Br. J. Pharmacol. 2013, 170:999-1013.
96. Sharman J.L., Mpamhanga C.P., Spedding M., Germain P., Staels B., Dacquet C., et al. IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Res. 2011, 39:D534-D8.
97. Shih J.C., Chen K. Regulation of MAO-A and MAO-B gene expression. Curr. Med. Chem. 2004, 11:1995-2005.
98. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 1999, 22:197-217.
99. Shih J.C., Wu J.B., Chen K. Transcriptional regulation and multiple functions of MAO genes. J. Neural Transm. 2011, 118:979-986.
100. Shumay E., Logan J., Volkow N.D., Fowler J.S. Evidence that the methylation state of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A enzyme in healthy men. Epigenetics 2012, 7:1151-1160.
101. Silverman R.B. Radical ideas about monoamine-oxidase. Acc. Chem. Res. 1995, 28:335-342.
102. Song M.S., Matveychuk D., Mackenzie E.M., Duchcherer M., Mousseau D.D., Baker G.B. An update on amine oxidase inhibitors: multifaceted drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 44:118-124.
103. Stoessel A., Schlenk M., Hinz S., Kueppers P., Heer J., Guetschow M., et al. Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4h-3,1-benzothiazin-4-ones. J. Med. Chem. 2013, 56:4580-4596.
104. Sturza A., Duicu O.M., Vaduva A., Danila M.D., Noveanu L., Varro A., et al. Monoamine oxidases are novel sources of cardiovascular oxidative stress in experimental diabetes. Can. J. Physiol. Pharmacol. 2015, 93:555-561.
105. Tan A.K., Ramsay R.R. Substrate-specific enhancement of the oxidative half-reaction of monoamine-oxidase. Biochemistry 1993, 32:2137-2143.
106. Tesson F., Limon-Boulez I., Urban P., Puype M., Vandekerckhove J., Coupry I., et al. Localization of I-2-imidazoline binding-sites on monoamine oxidases. J. Biol. Chem. 1995, 270:9856-9861.
107. Tyacke R.J., Fisher A., Robinson E.S.J., Grundt P., Turner E.M., Husbands S.M., et al. Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1h-imidazol-2-Yl)-1-methyl-1h-indole), for the imidazoline2 binding site. Synapse 2012, 66:542-551.
108. Upadhyay A.K., Borbat P.P., Wang J., Freed J.H., Edmondson D.E. Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-d-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy. Biochemistry 2008, 47:1554-1566.
109. Veitinger M., Oehler R., Umlauf E., Baumgartner R., Schmidt G., Gerner C., et al. A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype. Acta Neuropathol. 2014, 128:665-677.
110. Veitinger M., Varga B., Guterres S.B., Zellner M. Platelets, a reliable source for peripheral Alzheimer's disease biomarkers?. Acta Neuropathol. Commun. 2014, 2:65.
111. Vianello R., Repic M., Mavri J. How are biogenic amines metabolized by monoamine oxidases?. Eur. J. Org. Chem. 2012, 7057-7065.
112. Vucicevic J., Nikolic K., Dobricic V., Agbaba D. Prediction of blood-brain barrier permeation of alpha-adrenergic and imidazoline receptor ligands using pampa technique and quantitative-structure permeability relationship analysis. Eur. J. Pharm. Sci. 2015, 68:94-105.
113. Walker M.C., Edmondson D.E. Structure-activity-relationships in the oxidation of benzylamine analogs by bovine liver mitochondrial monoamine-oxidase-B. Biochemistry 1994, 33:7088-7098.
114. Wang L., Esteban G., Ojima M., Bautista-Aguilera O.M., Inokuchi T., Moraleda I., et al. Donepezil plus propargylamine+8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 2014, 80:543-561.
115. Weinreb O., Badinter F., Amit T., Bar-Am O., Youdim M.B.H. Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice. Neurobiol. Aging 2015, 36:2628-2636.
116. Wong W.K., Chen K., Shih J.C. Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation. J. Biol. Chem. 2003, 278:36227-36235.
117. Woodard C.M., Campos B.A., Kuo S.-H., Nirenberg M.J., Nestor M.W., Zimmer M., et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. Cell Rep. 2014, 9:1173-1182.
118. Wu Y., Kazumura K., Maruyama W., Osawa T., Naoi M. Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection. J. Neural Transm. 2015, 122:1399-1407.
119. Xie S.-S., Wang X., Jiang N., Yu W., Wang K.D.G., Lan J.-S., et al. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. Eur. J. Med. Chem. 2015, 95:153-165.
120. Youdim M.B.H. The path from anti Parkinson drug selegiline and rasagiline to multi-functional neuroprotective anti Alzheimer drugs ladostigil and M30. Curr. Alzheimer Res. 2006, 3:541-550.
121. Youdim M.B.H. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and M30 derived from rasagiline. Exp. Neurobiol. 2013, 22:1-10.
122. Youdim M.B.H., Finberg J.P. Implications of MAO-A and MAO-B inhibition for antidepressant therapy. Mod. Probl. Pharmacopsychiatry 1983, 19:63-74.
123. Youdim M.B.H., Reiderer P. Monoamine Oxidases and Their Inhibitors 2011, Academic Press.
124. Youdim M.B.H., Tipton K.F. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat. Disord. 2002, 8:247-253.
125. Youdim M.B.H., Edmondson D., Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006, 7:295-309.
126. Zajecka J.M., Zajecka A.M. A clinical overview of monoamine oxidase inhibitors: pharmacological profile, efficacy, safety/tolerability, and strategies for successful outcomes in the management of major depressive disorders. Psychiatr. Ann. 2014, 44:513-523.
127. Zecca L., Youdim M.B.H., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.
128. Zellner M., Baureder M., Rappold E., Bugert P., Kotzailias N., Babeluk R., et al. Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients. J. Proteome 2012, 75:2080-2092.
129. Zheng H., Amit T., Bar-Am O., Fridkin M., Youdim M.B.H., Mandel S.A. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. J. Alzheimers Dis. 2012, 30:1-16.
130. Zheng H., Gal S., Weiner L.M., Bar-Am O., Warshawsky A., Fridkin M., et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 2005, 95:68-78.
131. Zheng H., Youdim M.B.H., Fridkin M. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem. Biol. 2010, 5:603-610.